Germline microRNA-based signatures predict toxicity and response to anti-CTLA-4 therapy.

J Transl Med · 2025 · PMC12306077 · PMID 40721801

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

barely significantno p-value reported

The 0.2 threshold (twice what would be considered barely significant) is expected to be robust across data and prediction scenarios.

also in 875 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.